View in EDS HTML Full Text PDF Full Text

Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells.

Saved in:
Bibliographic Details
Title: Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells.
Authors: Sun, Shunrong1 (AUTHOR), Fulati, Wulipan1 (AUTHOR), Shen, Lin1 (AUTHOR), Wu, Min1 (AUTHOR), Huang, Zilan1 (AUTHOR), Qian, Wensi1 (AUTHOR), Chen, Pingping1 (AUTHOR), Hu, Yingwei1 (AUTHOR), Chen, Mingyue1 (AUTHOR), Xu, Yu1 (AUTHOR), Zhang, Hongdi1 (AUTHOR), Ma, Jiexian1 (AUTHOR) jiexianma@hotmail.com, Xie, Yanhui1 (AUTHOR) yanhuixie@163.com
Source: Cancer Medicine. Jun2023, Vol. 12 Issue 12, p12975-12985. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.5969